Published in Blood Weekly, July 12th, 2001
This drug continues to work well as an early-stage CML treatment. But, some clinical studies show that patients with advanced-stage CML initially respond to STI-571 and then suffer a relapse as the cancer becomes resistant to the drug.
Now, new research demonstrates exactly how this resistance develops, and may suggest ways to design even more effective drugs to treat CML.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.